Scientific Program

All sessions will take place in Grandhall 1 at the Grand Walkerhill Hotel.

Thursday, October 25, 2018

07:00-10:30 ITMIG Committee meetings open to all conference participants

  • 07:00 – 07:30: Education Committee Meeting
  • 07:30 – 08:30: Steering Committee Meeting
  • 08:30 – 09:30: Biology/Pathology Committee Meeting
  • 09:30 – 10:00: Database Committee Meeting
10:00 – 12:00 Local Hospital Visit, Asan Medical Center
17:30 Opening Reception

Friday, October 26, 2018

08:00 – 09:00 KSCTS Abstract Session in English
09:00 – 10:00 ITMIG I – KART Presentations

  • 09:00 – 09:20: Impact of lymph node dissection on thymic malignancy: The Korean Association for Research on the Thymus (KART) Database Study –Yoohwa Hwang
  • 09:20 – 09:40: Minimally invasive surgery of thymic tumors – Geun Dong Lee
  • 09:40 – 10:00: Technical advances of radiotherapy for thymic epithelial tumors – Jae Myoung Noh
10:00 – 10:30 Coffee Break
10:30 – 12:30 ITMIG II – Imaging

  • 10:30 – 11:00: ITMIG Projects – ITMIG Database and Other Updates
  • 11:00 – 11:20: Approach to Prevascular Mass – Nori Tomiyama
  • 11:20 – 11:35: Clinical TNM Staging of Thymic Epithelial Malignancies – Jeanne Ackman
  • 11:35 – 12:00: Determining extent of invasion and follow-up of thymic epithelial malignancies – Marcelo Benveniste
  • 12:00 – 12:20: Management of the incidentally detected prevascular mass – Soon Ho Yoon
  • 12:20 – 12:30: Imaging panel questions and answers – EM Maron, Nori Tomiyama, Jeanne Ackman, Marcelo Benveniste, Soon Ho Yoon 
12:30 – 13:30 Luncheon
13:30 – 15:00 ITMIG III – Abstracts

  • 13:30 – 13:40: Tumor Size as a Prognostic Factor in Limited Stage Thymic Epithelial Tumors: A Multicenter Analysis – Jae Kwang Yun
  • 13:40 – 13:50: Modified Subxiphoid Thoracoscopic versus Unilateral Thoracoscopic Approach for Early-stage Thymomas without MG – Jianyong Ding
  • 13:50 – 14:00: Compare two assessment criteria for thymic epithelial tumors after chemoradiotherapy – Xingwen Fan
  • 14:00 – 14:10: Predictors of Occult Pleural Dissemination Detected Intraoperatively in Patients with Thymic Tumors – Weigang Zhao
  • Prognostic factor of T3N0M0 thymic epithelial tumor with complete resection – Yi-Ting Yen
  • 14:10 – 14:20: Incidence and Pathological Features of Thymomathous Myasthenia Gravis after Thymectomy at a Tertiary-level Center – Arthur Vieira
  • 14:20 – 14:30: CD70 in thymic carcinoma: a promising diagnostic marker – Jumpei Kashima
  • 14:30 – 14:40: Thymic carcinoma: preliminary data of Next Generation Sequencing (NGS) analysis – Mirella Marino
  • 14:40 – 14:50: Gene expression profile reveals  new biomarker for novel diagnosis and therapy in thymic and pulmonary carcinomas. – Djeda Belharazem
15:30 – 17:30 Clinical decision making for minimally invasive approach

  • 15:30 – 15:45: Potential red flags for VATS and for RATS thymectomy – Alper Toker
  • 15:45 – 16:00: Panel discussion and summary – V Fang, Josh Sonett, Alper Toker, Marcin Zielinski

Developing a MIS program for invasive tumors

  • 16:00 – 16:10: Is there a threshold for getting over the learning curve for MIS for TET? – Josh Sonett
  • 16:10 – 16:20: Initiating a MIS TET program: case selection, simulation, proctorship – Franca Melfi
  • 16:20 – 16:30: Using CUSUM monitoring of a new program – Nuria Novoa
  • 16:30 – 16:45: Panel discussion on training – Josh Sonett, Franca Melfi, Nuria Novona, A Kirk, Young Soo Choi

Node dissection in an Era of Minimally Invasive Resection: Is it important?

  • 16:45 – 16:55: What extent of node sampling or dissection is appropriate? – In Kyu Park
  • 16:55 – 17:05: Difficulties in node assessment with MIS and potential solutions – Takashi Suda
  • 17:05 – 17:15 – Extent of node assessment and 9th edition refinement of TNM stage classification – Enrico Ruffini
  • 17:15 – 17:30: Panel discussion – In Kyu Park, Takashi Suda, Enrico Ruffini, Chang Yung Lee, Y Hwang, Meinoshin Okumura

Saturday, October 27, 2018

8:00 – 9:00 KSCTS Abstract session in English
9:00 – 10:00 ITMIG V – Pleural

  • 09:00 – 09:15: Chemotherapy for stage IVA thymic tumors: neoadjuvant or adjuvant, intrapleural or systemic? – Nicolas Girard
  • 09:15 – 09:30: Surgery and intrapleural therapy for stage IVA thymic tumors – S Cho
  • 09:30 – 09:45: Radiotherapy for stage IVA thymic tumors – Changlu Wang
  • 09:45 – 10:00: Panel Discussion – Nicolas Girard, S Cho, Changlu Wang, Vincent Fang
10:30 – 12:00 ITMIG VI – Medical Oncology/Basic Science

  • 10:30 – 10:50: Deciphering the biology of thymic tumors – Arun Rajan
  • 10:50 – 11:10: Next Generation Sequencing: is it useful for routine practice? – Nicholas Girard
  • 11:10 – 11:30: Systemic treatment of TET: Lessons from clinical trials – Keunchil Park
  • 11:30 – 11:50: Immune checkpoint inhibitors: how to move forward? – Arun Rajan
  • 11:50 – 12:00: Panel discussion – Nicolas Girard, Keunchil Park, Arun Rajan
13:00 – 14:00 ITMIG VII – Abstracts

  • 13:00 – 13:10: Comparison of factors affecting length of stay after surgery for thymic tumors: minimally invasive vs open surgeries – Kwon Joong Na
  • 13:10 – 13:20: The Importance of Measuring Acetylcholine Receptor Antibodies in Thymomas – Florit Marcuse
  • 13:20 – 13:30: Adjuvant chemotherapy improved survival of completely resected squamous thymic carcinoma – Wang Changlu
  • 13:30 – 13:40: MRI for the Follow-up of Treated Thymic Epithelial Malignancies – Ariel Kerpel
  • 13:40 – 13:50: The Role of Postoperative Radiotherapy in Stage II and III Thymoma: A Korean Multicenter Database Study – Seung Hwan Song
  • 13:50 – 14:00: A dosimetric comparison of VMAT and IMPT with and without aperture for thymic cancer – Kwanghyun Jo
14:00 – 17:00 ITMIG VII – Tumor Board

 

Poster Presentations

  • P-001 – Evaluation of the New TNM Staging System in 189 Patients with Thymic Carcinomas: Impact on Indication and Survival, Yu Yang, Fudan University Shanghai Cancer Center, China
  • P-002 – Thymoma in late-onset myasthenia gravis several years after initial normal chest imaging: two illustrative cases, Pedro Rodriguez Cruz, University of Oxford, UK
  • P-003 – Thymoma in early-onset myasthenia gravis following prior thymectomy with normal histology, Pedro Rodriguez Cruz, Oxford University, UK
  • P-004 – Cetuximab in pre-treated thymic epithelial tumors: a monocentric real life experience in selected population, Margaret Ottaviano, Rare Tumours Reference Center, University Federico II of Naples, Italy
  • P-005 – IL-8 can be used for the differential diagnosis of thymic epithelial tumors, Jianyong Ding, Zhongshan Hospital, China
  • P-006 – EGFR signature in B thymoma, Giovannella Palmieri, Rare Tumours Reference Center, University Federico II of Naples, Italy
  • P-007 – KIT mutation and expression in thymic carcinomas – clinicopathological and molecular analysis, Malgorzata Szolkowska, National Tuberculosis and Lung Diseases Research Institute, Poland
  • P-008 – Occurrence of a coexpression of the thymic markers CD5 and CD117 in a series of 251 lung squamous cell carcinomas ., Thierry Molina, Hôpital Necker, AP-HP, Paris descartes University, France
  • P-009 – Different pattern of PD-L1, STAT1 and STAT3 expression with survival in thymoma and thymic carcinoma, Yi-Ting Yen, National Cheng Kung University Hospital, Taiwan
  • P-010 – Abnormal wnt signaling in thymic epithelial tumors inhibits senescence and aging gene signatures, Xiaonan Zhang, Medical Faculty Mannheim, University of Heidelberg, Germany
  • P-011 – Thymoma treatment our experience., Fadil Gradica, University Hospital “Shefqet Ndroqi”, Albania
  • P-012 – Role of neutrophil-to-lymphocyte ratio on prognosis of early-stage, radically resected thymomas, Gianluca Perroni, Tor Vergata University, Italy
  • P-013 – Robotic thymectomy – does it really shorten the learning curve in minimally invasive thymectomy?, George Karimundackal, Tata Memorial Hospital, India
  • P-014 – The Role of Robotic Assisted Thoracoscopic Surgery in the Treatment of Large Malignant Thymic Tumours, Henrietta Wilson, Barts Health NHS Trust, UK
  • P-015 – Multidisciplinary management of recurrence after thymoma radical resection: an Italian experience, Enrico Ruffini, University of Torino, Italy
  • P-016 – Reconstruction of the superior vena cava in patients with thymic malignancies, Lei Yu, Beijing Tongren Hospital, Capital Medical University, China
  • P-017 – Minimal invasive thymectomy is feasible for the surgical treatment of large size thymic tumors, NING Xu, Shanghai Chest Hospital, China
  • P-018 – Is minimally invasive thymectomy an acceptable approach for locally advanced thymic malignances?, Zhitao Gu, Shanghai Chest Hospital, China
  • P-019 – Exploratory Study of Guiding Significance for The Technology of CD-DST in The Chemotherapy of Thymoma, Lei Yu, Beijing Tongren Hospital, Capital Medical University, China
  • P-020 – Long term outcomes in patients undergoing surgical resection of thymoma: a single institution experience, Hannah Ng, Tan Tock Seng Hospital, Singapore
  • P-021 – The significance of the Prognostic Nutrition Index in patients with thymic carcinoma or thymic neuroendocrine tumor, Masahiro Yanagiya, The University of Tokyo Graduate School of Medicine, Japan
Switch To Full Site